menu
    • menu

    Company profile for Pila Pharma

    NEW Drugs in Dev: 1
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    PILA PHARMA is a publicly held clinical stage pharmaceutical company based in Malmö, Sweden. The company is developing a TRPV1 antagonist, XEN-D0501, as a novel type of oral anti-diabetic agent. XEN-D0501 is a synthetic small molecule that was in-licensed in 2016. Prior to in-licensing, XEN-D0501 had been found to have a good safety profile in other (non-diabetic) patient groups. PILA PHARMA has to date completed two phase ...
    PILA PHARMA is a publicly held clinical stage pharmaceutical company based in Malmö, Sweden. The company is developing a TRPV1 antagonist, XEN-D0501, as a novel type of oral anti-diabetic agent. XEN-D0501 is a synthetic small molecule that was in-licensed in 2016. Prior to in-licensing, XEN-D0501 had been found to have a good safety profile in other (non-diabetic) patient groups. PILA PHARMA has to date completed two phase 2a clinical trials (PP-CT01 and PP-CT02), that both demonstrated that XEN-D0501 is well tolerated by people with type 2 diabetes. Further, PP-CT02, demonstrated that XEN-D0501 (administered as 4 mg BID for 28 days).

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Pila PharmaSweden Flag
    Country
    Country
    Sweden
    Address
    Address
    Västergatan 1 / 211 21 Malmö
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://pilapharma.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/pila-pharma-ab/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/PilaPharma

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Natural Products Expo

    Natural Products Expo

    Not Confirmed

    envelop Contact Supplier

    Natural Products Expo

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Pila Pharma Capital Raise Oversubscribed 293% for Obesity Work
    Pila Pharma Capital Raise Oversubscribed 293% for Obesity Work

    30 Oct 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-10-30/pila-pharma-s-capital-raise-oversubscribed-by-293-percent-to-fund-obesity-studies

    PHARMIWEB
    30 Oct 2025
    Share Share
    PHARMA AB – CEO Dorte X. Gram increases share holding
    PHARMA AB – CEO Dorte X. Gram increases share holding

    25 Feb 2022

    // PRESS RELEASE

    https://pilapharma.com/pharma-ab-ceo-dorte-x-gram-increases-share-holding-2/

    PRESS RELEASE
    25 Feb 2022
    Share Share
    PILA PHARMA publishes year-end report January 1 – December 31, 2021
    PILA PHARMA publishes year-end report January 1 – December 31, 2021

    18 Feb 2022

    // PRESS RELEASE

    https://pilapharma.com/pila-pharma-publishes-year-end-report-january-1-december-31-2021/

    PRESS RELEASE
    18 Feb 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search